DOI: 10.1055/s-00000094

Zeitschrift für Gastroenterologie

References

Heinemann V. et al.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Lancet Oncol 2014;
15: 1065-1075

Download Bibliographical Data

Access:
Access: